Skip to main content
. 2019 Apr 11;11:2997–3007. doi: 10.2147/CMAR.S199368

Figure 2.

Figure 2

BCL11A has strong oncogenic functions. (A) A Western blot assay was used to characterize the expression of BCL11A in BCL11A-overexpressing and control vector-transfected cells. shRNA against BCL11A effectively decreased BCL11A expression detected by Western blotting (left). BCL11A expression was confirmed by qRT-PCR (right), and β-actin was used as a loading control. (B) MTT assays were performed to compare the cell growth rates between BCL11A-overexpressing and control cells and between BCL11A-silenced and control cells. (C) Representative images of the increased foci formation ability induced by BCL11A in MCF-7 and MDAMB231 cell lines. Quantitative analyses of foci numbers are shown in the right panel. (D) Representative images of xenografts and a summary of tumor weight in nude mice. The weights of xenograft tumors are summarized in the right panel. All results are expressed as the mean ± SD of three independent experiments, *p<0.05; **p<0.01.